DeepMatter Group Plc is a big data and analysis company which has built a platform – DigitalGlassware™, focused on enabling reproducibility in chemistry. It continues to develop this software to deliver applications resulting in new optimised chemicals, materials and formulations in such commercially significant areas as pharmaceutical research, fine chemicals, scientific publications and teaching.
DeepMatter is at the forefront of the digitization of chemistry, which will ultimately see the enabling of an autonomous synthesis engine, the Chemputer™
|Therapautics Area||Multi Therapautics|
|Partner||Cancer Research UK, Astra Zeneca|
|Investment Portfolio||Fund Investment|
|Co-Investors||IP Group PLC|